Light chain amyloidosis (AL) is associated with high mortality, especially in patients with advanced cardiovascular involvement. It is caused by toxicity of misfolded light chain proteins (LC) in vascular, cardiac, and other tissues. There is no treatment to reverse LC tissue toxicity. We tested the hypothesis that nanoliposomes composed of monosialoganglioside, phosphatidylcholine, and cholesterol (GM1 ganglioside-containing nanoliposomes [NLGM1]) can protect against LC-induced human microvascular dysfunction and assess mechanisms behind the protective effect.
Identifer | oai:union.ndltd.org:arizona.edu/oai:arizona.openrepository.com:10150/621716 |
Date | 13 June 2016 |
Creators | Franco, Daniel A, Truran, Seth, Weissig, Volkmar, Guzman-Villanueva, Diana, Karamanova, Nina, Senapati, Subhadip, Burciu, Camelia, Ramirez-Alvarado, Marina, Blancas-Mejia, Luis M, Lindsay, Stuart, Hari, Parameswaran, Migrino, Raymond Q |
Contributors | Univ Arizona, Coll Med |
Publisher | WILEY-BLACKWELL |
Source Sets | University of Arizona |
Language | English |
Detected Language | English |
Type | Article |
Rights | Creative Commons Attribution Non-Commercial License |
Page generated in 0.002 seconds